Abstract
Beneficial effects of long-term HMG-CoA reductase inhibitor (statin) treatment for primary and secondary prevention of coronary heart disease (CHD) have been shown in several clinical trials and some of these statin trials in patients with established or high risk for CHD have shown that statins decrease stroke incidence. However, beneficial effects of statin for patients with chronic ischemic stroke and no histry of CHD remains to be clalified. The Japan Statin Treatment Against Recurrent Stroke (J-STARS) Study is a prospectivee randomised, open, blinded endpoint study designed to evaluate the effects of pravastatin 10mg/day in patients who preveously experienced an ischemic stroke other than cardioembolic infarction, but who do not have any CHD requiring statin treatment. We planed to enroll a total of 3, 000 patients, aged 45-80 years whc have serum cholesterol level of 180-240mg/dl. The primary endpoint is fatal and non-fatal stroke recurrence during the follow-up period of 5 year and the data collection phase of the study is expected to be completed by April 2010. Effects of statin on hs-CRP and carotid intima-media thickness will also be investigated as substudies of J-STARS. The detailed process for J-STARS protocol establishment have been presented in this symposium.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
